Aptevo Therapeutics (NASDAQ:APVO) Stock Price Passes Below 50 Day Moving Average – Time to Sell?

Aptevo Therapeutics Inc. (NASDAQ:APVO) shares passed below its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $4.88 and traded as low as $4.67. Aptevo Therapeutics shares last traded at $4.67, with a volume of 16,520 shares traded.

Analysts Set New Price Targets

A number of analysts have commented on APVO shares. Wall Street Zen raised Aptevo Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, March 29th. Weiss Ratings raised Aptevo Therapeutics from a “sell (e)” rating to a “sell (e+)” rating in a research report on Monday. One investment analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold”.

Aptevo Therapeutics Price Performance

The firm has a market capitalization of $5.84 million, a PE ratio of -0.02 and a beta of 1.68. The firm’s fifty day moving average is $4.89 and its two-hundred day moving average is $8.03.

Aptevo Therapeutics (NASDAQ:APVO) last posted its quarterly earnings data on Wednesday, May 13th. The biotechnology company reported ($6.41) EPS for the quarter, meeting the consensus estimate of ($6.41). As a group, equities research analysts predict that Aptevo Therapeutics Inc. will post -23.35 EPS for the current fiscal year.

Institutional Trading of Aptevo Therapeutics

A hedge fund recently bought a new position in Aptevo Therapeutics stock. Virtu Financial LLC acquired a new stake in Aptevo Therapeutics Inc. (NASDAQ:APVO) in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 38,282 shares of the biotechnology company’s stock, valued at approximately $56,000. Virtu Financial LLC owned 1.16% of Aptevo Therapeutics at the end of the most recent reporting period. 8.06% of the stock is owned by institutional investors and hedge funds.

About Aptevo Therapeutics

Aptevo Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Seattle, Washington, focused on the discovery and development of novel immunotherapies for oncology and autoimmune diseases. Founded in 2012 as a spin-off from Emergent BioSolutions, the company builds on expertise in protein engineering and translational research to create targeted biologics that engage the body’s immune system.

The company’s core technologies include the ADAPTIR platform, which enables the design of bispecific and multispecific protein scaffolds with customizable binding domains, and the KNOCKOUT platform, which incorporates non-natural amino acids to enhance therapeutic properties such as stability and half-life.